New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:10 EDTSUPNSupernus announces issuance of first use patents for SPN-812
Supernus Pharmaceuticals announced the issuance of a European patent and Canadian patent for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States.
News For SUPN From The Last 14 Days
Check below for free stories on SUPN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
07:38 EDTSUPNSupernus announces paragraph IV Abbreviated NDA filing for Trokendi XR
Subscribe for More Information
August 14, 2014
09:11 EDTSUPNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Kohl's (KSS), up 2.5%... Plug Power (PLUG), up 10%... Perrigo (PRGO), up 4.5%. HIGHER: Aruba Networks (ARUN), up 3% after shares upgraded at Stifel... KaloBios (KBIO), up 7.9% after publication shows EphA3 as target for anticancer therapy... Supernus (SUPN), up 4.4% after receiving FDA fast track designation for SPN-810. DOWN AFTER EARNINGS: Noodles & Company (NDLS), down 22%... Vipshop (VIPS), down 5.8%. LOWER: ExOne (XONE), down 10.7%, Voxeljet (VJET), down 6.6%, after earnings reports. Peers in the 3D space are lower as well, with Stratasys (SSYS) down 1% and 3D Systems (DDD) down 0.2%... Enphase Energy (ENPH), down 2.6% after filing to sell common stock for holders... InterMune (ITMN), down 3% after downgraded at Goldman following yesterday's advance on Bloomberg report that the company received takeover bids from Sanofi (SNY), Roche (RHHBY).
07:37 EDTSUPNSupernus receives FDA fast track designation for SPN-810
Supernus Pharmaceuticals announced that the United States Food and Drug Administration has granted fast track designation for SPN-810 for the treatment of impulsive aggression in attention deficit hyperactivity disorder. This product candidate is expected to enter Phase III testing, with patient dosing commencing during 2015.
August 12, 2014
09:21 EDTSUPNOn The Fly: Pre-market Movers
Subscribe for More Information
August 11, 2014
17:18 EDTSUPNSupernus raises FY14 revenue view to about $105M from $75M-$85M
Subscribe for More Information
17:16 EDTSUPNSupernus reports Q2 EPS 8c, may not compare to consensus (16c)
Reports Q2 revenue $29.68M, consensus $19.85M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use